InspireMD (NYSE:NSPR) Research Coverage Started at started coverage on shares of InspireMD (NYSE:NSPRFree Report) in a research report released on Tuesday. The firm issued a sell rating on the stock.

InspireMD Price Performance

NYSE NSPR opened at $2.54 on Tuesday. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.85. The company has a market capitalization of $63.32 million, a price-to-earnings ratio of -3.34 and a beta of 0.95. The company’s fifty day moving average price is $2.31 and its two-hundred day moving average price is $2.49.

InspireMD (NYSE:NSPRGet Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.06). InspireMD had a negative net margin of 350.35% and a negative return on equity of 55.12%. The company had revenue of $1.51 million for the quarter, compared to the consensus estimate of $1.38 million. During the same quarter last year, the company earned ($0.53) earnings per share. As a group, analysts anticipate that InspireMD will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. Mesirow Financial Investment Management Inc. purchased a new position in InspireMD, Inc. (NYSE:NSPRFree Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned about 0.13% of InspireMD as of its most recent filing with the Securities and Exchange Commission. 44.78% of the stock is owned by institutional investors.

About InspireMD

(Get Free Report)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.

Read More

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with's FREE daily email newsletter.